Thomas Gajewski to Drug-Related Side Effects and Adverse Reactions
This is a "connection" page, showing publications Thomas Gajewski has written about Drug-Related Side Effects and Adverse Reactions.
Connection Strength
0.741
-
First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies. Clin Cancer Res. 2017 07 01; 23(13):3269-3276.
Score: 0.431
-
Targeting molecular pathways to control immune checkpoint inhibitor toxicities. Trends Immunol. 2025 Jan; 46(1):61-73.
Score: 0.187
-
Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma. J Cancer Res Clin Oncol. 2017 Mar; 143(3):439-445.
Score: 0.107
-
Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol. 2009 Mar 01; 27(7):1075-81.
Score: 0.016